RAPID THERAPEUTIC SCIENCE LABORATORIES, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.005 USD | 0.00% |
|
0.00% | +21.95% |
Valuation
| Fiscal Period: December | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 1.595 | 0.4816 | 48.63 | 135.3 | 48.39 | 5.823 |
| Enterprise Value (EV) 1 | 1.617 | 3.315 | 51.57 | 135.8 | 50.18 | 9.654 |
| P/E ratio | -73.8 x | -0.39 x | -1.07 x | -46.3 x | -16.6 x | -3.24 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | - | - | - | 774,924,270 x | 90,621,207,865 x | - |
| EV / Revenue | - | - | - | 777,873,031 x | 93,978,853,933 x | - |
| EV / EBITDA | - | -24,429,460 x | -336,373,582 x | -53,265,619 x | -23,498,069 x | -7,789,598 x |
| EV / FCF | -118 x | -34.9 x | 2,640 x | 5,772 x | -217 x | -39.6 x |
| FCF Yield | -0.85% | -2.86% | 0.04% | 0.02% | -0.46% | -2.52% |
| Price to Book | -69.6 x | -0.17 x | -0.12 x | -12,120 x | -35 x | -1.85 x |
| Nbr of stocks (in thousands) | 108 | 48.2 | 6,274 | 7,214 | 7,743 | 7,765 |
| Reference price 2 | 14.71 | 10.00 | 7.750 | 18.75 | 6.250 | 0.7500 |
| Announcement Date | 17-07-14 | 18-12-06 | 19-07-09 | 21-03-16 | 22-03-16 | 23-03-30 |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|
| Net sales | - | - | - | 0.1746 | 0.000534 | - |
| EBITDA | - | -0.1357 | -0.1533 | -2.549 | -2.136 | -1.239 |
| EBIT 1 | -0.0216 | -0.1521 | -0.1697 | -2.659 | -2.17 | -1.263 |
| Operating Margin | - | - | - | -1,523.2% | -406,422.28% | - |
| Earnings before Tax (EBT) 1 | -0.0216 | -2.553 | -0.3488 | -2.736 | -2.868 | -1.795 |
| Net income 1 | -0.0216 | -2.553 | -0.3488 | -2.736 | -2.868 | -1.795 |
| Net margin | - | - | - | -1,567.51% | -537,056.74% | - |
| EPS 2 | -0.1994 | -25.88 | -7.243 | -0.4053 | -0.3759 | -0.2317 |
| Free Cash Flow 1 | -0.0137 | -0.0949 | 0.0195 | 0.0235 | -0.2313 | -0.2437 |
| FCF margin | - | - | - | 13.48% | -43,310.86% | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 17-07-14 | 18-12-06 | 19-07-09 | 21-03-16 | 22-03-16 | 23-03-30 |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|
| Net Debt 1 | 0.02 | 2.83 | 2.94 | 0.51 | 1.79 | 3.83 |
| Net Cash position 1 | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | -20.88 x | -19.18 x | -0.2019 x | -0.8395 x | -3.091 x |
| Free Cash Flow 1 | -0.01 | -0.09 | 0.02 | 0.02 | -0.23 | -0.24 |
| ROE (net income / shareholders' equity) | 179% | 177% | 11.6% | 27.6% | 412% | 79.4% |
| ROA (Net income/ Total Assets) | -155% | -565% | -769% | -121% | -73.1% | -35.5% |
| Assets 1 | 0.0139 | 0.4517 | 0.0454 | 2.254 | 3.925 | 5.063 |
| Book Value Per Share 2 | -0.2100 | -59.40 | -65.80 | -0 | -0.1800 | -0.4000 |
| Cash Flow per Share 2 | 0.0700 | 0.2600 | 0.0300 | 0.0700 | 0.0200 | - |
| Capex | - | 0.04 | - | 0.14 | 0.29 | 0.04 |
| Capex / Sales | - | - | - | 81.53% | 54,781.09% | - |
| Announcement Date | 17-07-14 | 18-12-06 | 19-07-09 | 21-03-16 | 22-03-16 | 23-03-30 |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| +21.95% | 94.93K | |
| +39.33% | 6.11B | |
| -18.38% | 4.35B | |
| -9.17% | 3.19B | |
| +3.98% | 3.15B | |
| -3.41% | 2.51B | |
| +48.74% | 1.98B | |
| -4.82% | 1.74B | |
| -1.24% | 1.63B | |
| -8.96% | 1.6B |
- Stock Market
- Equities
- RTSL Stock
- Financials Rapid Therapeutic Science Laboratories, Inc.
